With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ...

The FDA has approved Celcuity's gedatolisib (Revtorpyk) for hormone receptor-positive, HER2-negative breast cancer, positioning it as a potential blockbuster with efficacy superior to competing agents and plans to expand into first-line use and prostate cancer indications.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.